Fred M. Powell
Net Worth
Last updated:
What is Fred M. Powell net worth?
The estimated net worth of Mr. Fred M. Powell is at least $9,341,249 as of 12 Nov 2020. He owns shares worth $3,613,739 as insider and has received compensation worth at least $5,727,510 in Antares Pharma, Inc..
What is the salary of Fred M. Powell?
Mr. Fred M. Powell salary is $636,390 per year as Executive Vice President & Chief Financial Officer in Antares Pharma, Inc..
How old is Fred M. Powell?
Mr. Fred M. Powell is 64 years old, born in 1961.
What stocks does Fred M. Powell currently own?
As insider, Mr. Fred M. Powell owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Antares Pharma, Inc. (ATRS) | Executive Vice President & Chief Financial Officer | 646,465 | $5.59 | $3,613,739 |
What does Antares Pharma, Inc. do?
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.
Fred M. Powell insider trading
Antares Pharma key executives
Antares Pharma, Inc. executives and other stock owners filed with the SEC:
- Mr. Fred M. Powell (64) Executive Vice President & Chief Financial Officer
- Mr. Peter J. Graham (58) Executive Vice President of HR, Gen. Counsel, Chief Compliance Officer & Corporation Sec.
- Mr. Robert F. Apple (59) Chief Executive Officer, Pres & Director